10-Q
Quarterly Report
AGENUS INC
AGEN
NASDAQ
CIK: 1098972
File #: 000-29089
Balance Sheet
59 line items · 2 periods
XBRL
| Item | Mar 31, 2026 | Dec 31, 2025 |
|---|---|---|
ASSETS | ||
Cash and cash equivalents | 34,996,000 | 2,998,000 |
Institutional Money Market Funds - Estimated Fair Value | 435,000 | 417,000 |
Estimated Fair Value | 435,000 | 417,000 |
Institutional Money Market Funds - Cost | 435,000 | 417,000 |
Cost | 435,000 | 417,000 |
Zydus agreements escrow receivable (Note R) | 7,500,000 | 0 |
Zydus Lifesciences Ltd - Zydus Agreements | 7,500,000 | — |
Zydus transaction contract assets | 40,000,000 | 0 |
Accounts receivable | 6,562,000 | 1,831,000 |
Prepaid expenses | 4,188,000 | 785,000 |
Related Parties | 0 | 5,179,000 |
Assets held for sale | 0 | 121,554,000 |
Other current assets | 2,038,000 | 1,089,000 |
Total current assets | 95,284,000 | 133,436,000 |
MiNK Therapeutics, Inc. | 10,022,000 | — |
Property, plant and equipment, net of accumulated amortization and depreciation of $47,893 and $47,468 at March 31, 2026 and December 31, 2025, respectively | 14,947,000 | 15,470,000 |
Operating lease right-of-use assets | 7,458,000 | 7,744,000 |
Goodwill | 24,092,000 | 24,092,000 |
Acquired intangible assets, net of accumulated amortization of $19,675 and $17,325 at March 31, 2026 and December 31, 2025, respectively | 2,959,000 | 3,037,000 |
Equity method investment in MiNK Therapeutics, Inc. | 22,927,000 | 24,277,000 |
Related Parties | 15,776,000 | 15,435,000 |
MiNK Therapeutics, Inc. | 15,800,000 | — |
Other long-term assets | 3,013,000 | 3,307,000 |
Total assets | 186,456,000 | 226,798,000 |
LIABILITIES AND STOCKHOLDERS' DEFICIT | ||
Current portion, long-term debt | 30,193,000 | 44,655,000 |
Promissory Note | 24,482,000 | 24,052,000 |
Debentures | 146,000 | 146,000 |
Other services | 548,000 | 104,000 |
2015 Subordinated Notes | 5,017,000 | 10,353,000 |
Zydus Promissory Note | — | 10,000,000 |
Current portion, liability related to sale of future royalties and milestones | 109,405,000 | 109,323,000 |
Current portion, operating lease liabilities | 1,054,000 | 1,034,000 |
Accounts payable | 71,084,000 | 82,987,000 |
Accrued liabilities | 36,987,000 | 34,223,000 |
Liabilities held for sale | 0 | 50,738,000 |
Other current liabilities | 514,000 | 529,000 |
Total current liabilities | 249,237,000 | 323,489,000 |
MiNK Therapeutics, Inc. | 7,287,000 | — |
Liability related to sale of future royalties and milestones, net of current portion | 153,985,000 | 169,660,000 |
Deferred revenue, net of current portion | 1,143,000 | 1,143,000 |
Operating lease liabilities, net of current portion | 9,827,000 | 10,108,000 |
Other long-term liabilities | 247,000 | 259,000 |
STOCKHOLDERS" DEFICIT | ||
Series A-1 convertible preferred stock | 0 | 0 |
Common stock, par value $0.01 per share; 800,000,000 shares authorized; 38,521,761 and 35,320,397 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 385,000 | 353,000 |
Additional paid-in capital | 1,922,370,000 | 1,911,740,000 |
Accumulated other comprehensive loss | (437,000) | (439,000) |
Accumulated deficit | (2,143,539,000) | (2,182,765,000) |
Total stockholders' deficit attributable to Agenus Inc. | (221,221,000) | (271,111,000) |
Non-controlling interest | (6,762,000) | (6,750,000) |
Total stockholders' deficit | (227,983,000) | (277,861,000) |
Accumulated Deficit | (2,143,539,000) | (2,182,765,000) |
Common Stock | 385,000 | 353,000 |
Additional Paid-in Capital | 1,922,370,000 | 1,911,740,000 |
Accumulated Other Comprehensive Income (Loss) | (437,000) | (439,000) |
Non-controlling Interest | (6,762,000) | (6,750,000) |
Total liabilities and stockholders' deficit | 186,456,000 | 226,798,000 |